Further · Closer · Together

2ND QUARTER AND FIRST HALF YEAR FINANCIAL REPORT 2012

REGULATED INFORMATION

JULY 27 2012, 7.30 AM BRUSSELS TIME

SOLVAY

SOLVAY GROUP*

2ND QUARTER 2012 BUSINESS REVIEW

Highlights

Growth engines and highly resilient businesses driving the good performance in Q2

- Net sales stable at EUR 3,331 million yoy with prices +2%, volumes (6)% and forex +4%.

- REBITDA[1] at EUR 565 million (17% margin) up by 8% versus Q1'12 and (6)% down yoy against a peak comparable
  - Record results in Specialty Polymers and Consumer Chemicals driven by strong pricing power
  - Sustained high-level performance in Essential Chemicals and Acetow & Eco Services
  - Persisting difficult market conditions, volume and margin squeeze for Vinyls and Polyamide

- Good progress of the integration and the delivery of cost efficiencies (EUR 55 million[2] in H1'12)
- Management of assets (sale of PipeLife and corporate premises) resulting in after-tax capital gains of EUR 113 million
- Adjusted Net Income (Group Share) of EUR 244 million (IFRS Net Income of EUR 222 million)
- Free Cash Flow of EUR 138 million and stable Net Debt of EUR 1.8 billion

1. REBITDA: operating result before depreciation and amortization, non-recurring items, financial charges and income taxes.
2. versus 2010 pro forma cost base

Quote of the CEO

In the current uncertain environment, the good performance achieved in the quarter highlights the Group's solid fundamentals. Our growth engines continued to deliver strongly, mostly compensating for challenged cycle-sensitive businesses. We reinforced our expansion in high-growth countries, namely in China and India, with the commissionning of new production and R&D facilities. The building of the new Solvay is now well on-track and we are committed to realize our value-creative ambition.

Outlook

Business dynamics should remain healthy for our growth engines and challenging for our cycle sensitive businesses. Despite the slowing in demand observed in June in some business segments, the ongoing major transformation of the Group combined with our ability to fully deliver on our cost saving targets lead Solvay to reiterate its expectation to achieve a full year REBITDA similar to the strong 2011 pro forma level.

* Footnote applicable to the entire document: All references to year-on-year (yoy) evolution must be understood on a pro forma basis for 2011, as if the acquisition of Rhodia had become effective from the 1st of January 2011. On a pro forma basis Solvay 2011 historical figures were restated in order to have harmonized accounting policies among the two former Groups, policies that are to be used by the new Solvay going forward. Pro forma results exclude impacts from i) purchase price allocation entries; ii) non-recurring acquisition costs related to the Rhodia transaction and iii) financial revenues on cash deposits and investments. Adjusted Profit & Loss indicators exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.

All period changes throughout this document are to be deemed on a year-on-year bases unless otherwise stated.

SOLVAY GROUP
2ND QUARTER 2012 BUSINESS REVIEW

Key data (in million EUR)	Adjusted[1] 2Q 2012	Pro Forma[2] 2Q 2011	YoY evolution (%)/times	Adjusted[1] 1H 2012	Pro Forma[2] 1H 2011	YoY evolution (%)
Net Sales[3]	3,331	3,296	1%	6,570	6,440	2%
REBITDA[4]	565	604	(6)%	1,088	1 178	(8)%
REBIT	391	449	(13)%	744	860	(14)%
Non-recurring items	75	9	8x	6	25	(75)%
EBIT	466	458	2%	750	885	(15)%
Net financial expenses	(110)	(84)	31%	(189)	(165)	15%
Result before taxes	356	376	(5)%	559	721	(22)%
Income taxes	(99)	(79)	25%	(179)	(170)	6%
Net result from continuining operations[5]	257	297	(14)%	380	551	(31)%
Net result from discontinued operations	1	(45)		3	(44)	(106)%
Net income	258	252	2%	383	507	(25)%
Non controlling interests	(14)	(22)	36%	(23)	(37)	38%
Net income, Group share	244	230	6%	360	470	(23)%
Free cash flow[6]	138	98	41%	190	185	3%

1. Adjusted performance indicators exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.
2. Pro forma figures shown in the income statement (a) as if the acquisition had become effective from 1st of January 2011, (b) harmonizing accounting principles and (c) excluding the Purchase Price Allocation (PPA) impacts.
3. Net sales comprise the sales of goods and value added services corresponding to Solvay's know-how and core business. Net sales exclude other revenues primarily comprising commodity and utility trading transactions and other revenue deemed as incidental by the Group.
4. REBITDA: operating results before depreciation and amortization, non-recurring items, financial charges and income taxes.
5. The net results from discontinued operations is linked to post-closing adjustments subsequent to the sale of the pharmaceutical activities.
6. Cash flow from operating activities (including dividends from associates and joint ventures) + cash flow from investing activities (excluding acquisitions and sales of subsidiaries and other investments).

Net sales

EUR **3,331** million

+1%

REBITDA

EUR **565** million

(6)%

Adj. net income

EUR **258** million

Adj. EPS (basic)

EUR **2.96**

YoY evolution (%) compared with pro forma 2nd quarter 2011

SOLVAY GROUP
2ND QUARTER AND 1ST SEMESTER 2012

Key data (in million EUR)	Adjusted 2Q 2012	YoY evolution (%)	Adjusted 1H 2012	YoY evolution (%)
Net sales	**3,331**	**1%**	**6,570**	**2%**
Plastics	998	1%	1,949	0%
Chemicals	760	5%	1,496	4%
Rhodia	1,574	(1)%	3,125	2%
REBITDA	**565**	**(6)%**	**1,088**	**(8)%**
Plastics	146	(27)%	283	(23)%
Chemicals	139	8%	294	10%
Rhodia	318	3%	579	(5)%
New Business Development	(13)	26%	(21)	7%
Corporate and Business Support	(25)	8%	(45)	5%

Business review – 1st semester 2012

Net sales reached EUR 6,570 million, up by 2% versus the first semester 2011. This improvement is reflected in the Chemicals and Rhodia sector, whilst net sales remained stable in Plastics. The (4)% lower volumes were more than compensated by average selling price increases of +3%, favourable currency effects of +2% and scope changes of +1% The volume decline is mainly to be ascribed to the very high last year's comparison basis and to the economic slowdown.

REBITDA amounted to EUR 1,088 million down by (8)% versus the very demanding comparable of last year in the Plastics and Rhodia sector. In Plastics, REBITDA declined by 23% due to the demand decrease and margin squeeze in Vinyls. REBITDA of the Chemicals sector came in at EUR 294 million, a 10% improvement year on year, that was supported by the sustained performance of Essential Chemicals. The (5)% lower REBITDA of the Rhodia sector reflects margin squeeze in Polyamide Materials and exceptionnal situation at Rare Earth in 2011, which was not fully compensated for by the good growth in Consumer Chemicals and Acetow & Eco Services. Group REBITDA margin on net sales amounted to 16.6% compared with 18.3% in the 1st semester of 2011.

REBITDA of **New Business Development** amounted to EUR (21) million; it reflects the research & development efforts made in promising and important areas for development of the Group outside its traditional activities.

REBITDA of **Corporate and Business Support** amounted to EUR (45) million.

NEW INNOVATION CENTRE IN INDIA

Solvay inaugurated its new RD&T Centre at Savli, Gujarat State, India. The Centre will focus on the development of high-performance polymers, organic chemistry, nano composites and green chemistry. It will employ over 200 researchers when fully operational.

The Centre has also established three fellowships for research in sustainable chemistry, nano technology and polymer science at the Maharaja Sayajirao University in Vadodara.

PLASTICS
2ND QUARTER 2012 BUSINESS REVIEW

Highlights

Specialty Polymers

- Relentless business momentum with Net Sales and REBITDA at a record EUR 352 million and EUR 105 million respectively. Sustained strong REBITDA margin of 30%
- Operational excellence programs contributing to the results growth

Vinyls

- Continued suffering from low demand and difficult market conditions
- Differentiated business dynamics by region

Key data (in million EUR)	Adjusted 2Q 2012	YoY evolution (%)	Adjusted 1H 2012	YoY evolution (%)
Net sales	**998**	**1%**	**1,949**	**0%**
Specialty Polymers	352	9%	675	5%
Vinyls	645	(3)%	1274	(2)%
Vinyls Europe	383	-	735	(4)%
Vinyls Asia	87	(7)%	181	14%
Vinyls South America	134	(4)%	273	(4)%
Plastics Integration	42	(15)%	85	(11)%
REBITDA	**146**	(27)%	**283**	(23)%
Specialty Polymers	105	6%	197	1%
Vinyls	41	(58)%	85	(49)%

Net sales

EUR **998** million

+1%

REBITDA

EUR **146** million

(27)%

Against strong comparison

YoY evolution (%) Compared with pro forma 2nd quarter 2011

Specialty Polymers

Net sales of Specialty Polymers hit a new record in Q2'12 increasing by 9% yoy. Prices increased by 3% and volumes remained stable compared to the same period last year. The 2nd quarter of 2012 benefited also from positive foreign exchange impacts of 7%.

By end-markets, Oil & Gas, Smart Devices, Water, Healthcare and Advanced Transportation were highly dynamic driven by ever-increasing enhanced performance demands. The Consumer, Automotive and Industrial markets remained highly resilient while Construction and Electric/Electronics markets stood subdued. Numerous operational excellence programs have been implemented and have already started to contribute to the results growth. The innovation development pool remains healthy with significant new promising projects to be launched in the coming months.

REBITDA amounted to EUR 105 million up by 6% compared to the 2nd quarter of last year. The REBITDA margin on sales stood at 30%, similar to the high level reached in Q2'11. The profitability of these activities is driven by favourable product mix.

2Q'12 net sales % YoY evolution



Vinyls

Net sales of Vinyls amounted to EUR 645 million, 3% up sequentially, but down (3)% compared to the high level of 2nd quarter 2011. Total volume dropped by (9)% yoy. In Europe, demand in PVC weakened and stood comparable to the the rock-bottom levels reached in Q2'09. The anticipation of price variations led to volatility. At the same time, demand remained low in Argentina but recovered slightly in Brazil supported by Brazilian government's economic measures and the Real devaluation. In Thailand the production unit of Vinythai runs at full capacity.

REBITDA amounted to EUR 41 million, down (58) % from the strong 2nd quarter 2011. In Europe, SolVin improved its spread versus the historically lowest point of Q1'12. Solvay Indupa's results suffered from fierce price competition in Brazil, preventing any margin expansion despite demand recovery and supportive Brazilian Real devaluation for the domestic industry. Furthemore, activity in Argentina suffered from shortage of ethylene. Vinythai continued to deliver a strong operating result despite some PVC demand slowdown observed lately in North East Asia.

2Q'12 net sales % YoY evolution



Specialty polymers compounding plant in China now on stream

The pecialty polymers compounding plant at Changshu, China, is turned operational in Q2'12 to serve the growing demand for compounds to be used in electronics, automotive, consumer and industrial applications. The plant produces compounds of Amodel® polyphthalamide (PPA), Ixef® polyarylamide (PARA) and Kalix® (modified PARA).

On the same site in Changshu, Solvay is building a specialty polymers production plant for SOLEF® Polyvinylidene Fluoride (PVDF), TECNOFLON® Fluoroelastomers (FKM) and their essential monomer VF2, expected to come on stream in 2014.

CHEMICALS
2ND QUARTER 2012 BUSINESS REVIEW
Highlights

- Essential Chemicals
  - REBITDA EUR 120 million improved by 18% year on year thanks to pricing
  - REBITDA margin on sales: 20%
  - Ramp up of Epirerol® plant in Thailand
- Special Chemicals
  - Fluorchemicals gradually recovering. Improvement supported by recovery in fluorspar supply conditions

Key data (in million EUR)	Adjusted 2Q 2012	YoY evolution (%)	Adjusted 1H 2012	YoY evolution (%)
Net sales	**760**	**5%**	**1,496**	**4%**
Essential Chemicals	597	7%	1,176	5%
EMEA[1]	366	*	741	*
North America	131	*	256	*
South America	42	*	74	*
Asia Pacific	57	*	105	*
Special Chemicals	163	-	320	3%
REBITDA	**139**	**8%**	**294**	**10%**
Essential Chemicals	120	18%	262	22%
Special Chemicals	20	(25)%	32	(35)%

1. Europe, Middle-East and Africa
* Irrelevant due to scope changes among regions

Net sales

EUR 760 million

+5%

REBITDA

EUR 139 million

+8%

YoY evolution (%) Compared with pro forma 2nd quarter 2011

Essential Chemicals

Net sales of Essential Chemical amounted to EUR 597 million, up by 7% compared to the 2nd quarter of 2011

• The demand for **soda ash** remained overall at a good level. A slowdown for flat glass experienced in Europe at the end of the quarter was compensated by good volumes and favorable mix and volumes in export markets. Demand in China somewhat weakened. Bicarbonate sales increased. Net sales of soda ash and bicarbonate also benefited from price increases, both in Europe and in the USA

• Demand for **caustic soda** remained satisfactory while supply improved versus 1Q'12. The selling prices decreased but remained at a level well above last year

• Activities in **epichlorohydrin** were impacted by maintenance activities in Tavaux while the new Epicerol® plant in Thailand progressively increased its operating rates. Epicerol® technology is highly appreciated by customers resulting in sold out activity levels.

• In **hydrogen peroxide** net sales were similar to those of the 2nd quarter 2011. Volumes remained sustained by good demand from pulp and paper though this industry is slowing down in Europe. The other end markets such as the chemical and the mining industry as well as environmental applications continued to perform well. Selling prices of hydrogen peroxide remained stable qoq but rose yoy, both in Europe and in the United States.

REBITDA amounted to EUR 120 million, up by 18% compared to the 2nd quarter 2011. The higher selling prices in an environment of globally sustained demand, coupled with stabilizing energy costs accounted for the increased operating performance.

Special Chemicals

Net sales amounted to EUR 163 million, which is in line with the 2nd quarter of 2011,

REBITDA amounted to EUR 20 million, compared to EUR 12 million in the 1st quarter of 2012 and EUR 26 million in Q2'11. Fluorchemicals gradually recovered from the lows posted at the end of 2011. The improvement was supported by the recovery in the fluorspar supply conditions.

Operating results were impacted by the negative performance of the Life Science division.

Special Chemicals - 2Q'12 net sales % YoY evolution



Essential Chemicals - 2Q'12 net sales % YoY evolution



Bio-based epichlorohydrin plant to serve China, the world's biggest market

Solvay's affiliate Vinythai will build a new epichlorohydrin production plant based on Solvay's proprietary bio-based Epicerol® technology in Taixing, China. The Chinese epichlorohydrin market is expected to grow on annual basis by 8% and represent 35% of total world demand in 2016. The 100,000 tons p/a plant requires an investment of EUR 155 million and should become operational in the second half of 2014.
The plant will use as feedstock natural glycerin obtained as by-product from the production of biofuels. The Epicerol® technology is protected by 1000 patent titles, many of them already granted in different parts of the world.

RHODIA

2ND QUARTER 2012 BUSINESS REVIEW

Highlights

- Record results driven by Consumer Chemicals and Acetow & Eco Services
- Excellent pricing power across businesses except polyamide. Without the later, Rhodia pricing power posted at EUR 20 million net positive REBITDA impact in the quarter, fully offset by Polyamide's EUR (26) million margin squeeze

Key data (in million EUR)	Adjusted 2Q 2012	YoY evolution (%)	Adjusted 1H 2012	YoY evolution (%)
Net sales	**1,574**	(1)%	**3,125**	2%
Consumer Chemicals	631	5%	1,229	5%
Advanced Materials	226	4%	464	16%
Polyamide Materials	440	(7)%	898	(2)%
Acetow & Eco Services	236	10%	455	8%
Energy Services	40	(18)%	80	(21)%
REBITDA	**318**	3%	**579**	(5)%
Consumer Chemicals	156	59%	262	38%
Advanced Materials	47	(33)%	96	(22)%
Polyamide Materials	43	(30)%	82	(37)%
Acetow & Eco Services	73	41%	127	29%
Energy Services	24	(40)%	57	(32)%
Corporate & Others	(26)	98%	(44)	133%

Net sales

EUR **1,574** million

(1)%

REBITDA

EUR **318** million

+3%

YoY evolution (%) Compared with pro forma 2nd quarter 2011

Consumer Chemicals

Consumer Chemicals reported **net sales** of EUR 631 million; up by 5% compared to last year.

Novecare continued its strong performance. In addition to guar-based formulations' exceptional dynamics serving the Oil & Gas market, the Home & Personal Care and the Industrial segments contributed to the strong performance of Novecare in the quarter. The ongoing significant demand for guar products allows Novecare to get customers' recognition for its differentiating value proposition concerning guar procurement. Coatis posted stable sales year on year with strong phenol activity despite the slowdown in production related to an industrial incident occurred in Paulinia. Aroma Performance continues implementing its strategic Food Safety repositioning.

REBITDA amounted to EUR 156 million, up by 59% compared to 2nd quarter 2011 mainly driven by Novecare which enjoyed strong volumes and good pricing power. While Aroma was impacted by less favorable conditions, Coatis faces a high reference from 2Q'11. REBITDA margin improved to the exceptionally high level of 25% compared to 16% last year.

2Q'12 net sales % YoY evolution



Advanced Materials

Net sales amounted to EUR 226 million, up by 4% year-on-year. Strong pricing and favourable currency developments were partly offset by lower volumes. Volume was reported down by (19)% mostly to be ascribed to Rare Earths, and specifically to its Electronic business reflecting both, global softer demand and a reposition of the business from high volume-low added value segments to higher added value segments. Mixed Oxydes demand for Auto catalysis customers within Rare Earths remained strong. Silica's volume was negatively impacted by slowing demand, particularly in Europe

REBITDA amounted to EUR 47 million, down by (33) % compared to 2nd quarter 2011 due to lower volumes in Electronics served by Rare Earths, mainly explained by peak demand during 1H'11. Pricing power is positive in both Silica and Rare Earths. REBITDA margin reached 21%, and is as anticipated, lower than the 33% margin achieved under last year's exceptional pricing conditions.

Rare Earth Systems has a unique and optimized competitive sourcing which combines presence in China and technological edge recycling know-how.

2Q'12 net sales % YoY evolution



Rhodia, Valeo and PSA Peugeot Citroën demonstrate the environmental benefits of recycled Technyl® polyamide

Rhodia, Valeo and PSA combined their savoir-faire to carry out a multi-criteria analysis on the entire life cycle of the fan and shroud assembly, an important engine cooling component for the new Peugeot 208. Manufactured by Valeo, the part uses recycled Technyl® polyamide (PA) from Rhodia Engineering Plastics.
The study compared the environmental impact of using recycled Technyl® PA with a standard Technyl® grade. It assessed the whole value chain emphasizing on seven key environmental criteria*. The results demonstrate the benefits range from -9% to -28% on those seven criteria when selecting and using recycled Technyl® PA.

* Climate change, the depletion of non-renewable resources, the impact on the diminution of the ozone layer, acidification, eutrophication, the consumption of primary energy and photochemical oxidation

Polyamide Materials

Net sales of EUR 440 million were down by (7) % yoy. Overall volumes were comparable with Q1'12, including the impact from the Force Majeure in Paulina in Adipic Acid but down by (7) % compared to Q2'11. P&I and EP volumes decreased due to slowing demand in Europe and Brazil, whilst Fibras is recovering.

REBITDA decreased to EUR 43 million compared to EUR 62 million last year. Margin erosion and the shutdown in Paulinia are the main factors behind the lower performance compared to the same period last year. The shutdown of our Adipic Acid manufacturing in Paulinia following an explosion adversely impacted the Group REBITDA by EUR (9)million in the quarter. Most of the impact is reported in Rhodia's Corporate & Others due to self-insurance. An equivalent negative effect is expected in the second part of the year.

2Q'12 net sales % YoY evolution



Acetow & Eco Services

Acetow & Eco Services reported **net sales** of EUR 236 million, a 10% increase compared to the 2nd quarter of 2011. Volume decline of (4) % was fully offset by price increases of 6% and favourable foreign exchange of 9%.

Eco Services reported strong activity levels corresponding to the usual high seasonality.

REBITDA amounted to EUR 73 million, up by 41% compared to last year driven by strong pricing power and more favourable mix in both segments. Within the cluster, Acetow benefited from good product mix and the first sales of innovative higher added value coloured tow.

2Q'12 net sales % YoY evolution



Energy Services

Energy Services reported **REBITDA** of EUR 24 million compared to EUR 40 million in the 2nd quarter of 2011. A good level of CER sales volumes, well in line with full year production/sales expectations of 14 million tonnes was realized. However, volumes were lower than last year (approx. 35%) because 2nd quarter 2011 had benefited from a faster certification process.

Despite less favorable CO_2 market pricing conditions, the year on year effective prices shortfall was limited by the hedging policy. Average CER prices realised over the quarter were 10.5 EUR per ton.

2Q'12 net sales % YoY evolution



CONSOLIDATED FINANCIAL STATEMENTS
INCOME STATEMENT 2ND QUARTER

	IFRS		Adjusted[1]	Pro forma[2]
	2012	2011	2012	2011
Sales	**3,418**	**1,718**	**3,418**	**3,380**
Other non-core revenues	88	6	88	84
Net sales	**3,331**	**1,713**	**3,331**	**3,296**
Cost of goods sold	(2,706)	(1,353)	(2,706)	(2,608)
Gross margin	**713**	**365**	**713**	**772**
Commercial and administrative costs	(293)	(126)	(293)	(286)
Research and development costs	(68)	(31)	(68)	(51)
Other operating gains and losses	(52)	(2)	(19)	(6)
Earnings from associates and joint ventures accounted for using the equity method	59	13	59	20
REBITDA	**565**	**304**	**565**	**604**
REBIT	**358**	**219**	**391**	**449**
Non-recurring items	75	14	75	9
EBIT	**433**	**233**	**466**	**458**
Cost of borrowings	(50)	(36)	(50)	(54)
Interest on lendings and short-term deposits	4	11	4	8
Other gains and losses on net indebtedness	(5)	(3)	(5)	(6)
Cost of discounting provisions	(59)	(12)	(59)	(32)
Income/loss from available-for-sale investments	(1)	1	(1)	1
Result before taxes	**322**	**195**	**356**	**376**
Income taxes	(88)	(19)	(99)	(79)
Result from continuing operations	**234**	**176**	**257**	**297**
Result from discontinued operations	1	(45)	1	**(45)**
Net income	**236**	**131**	**258**	**252**
Non-controlling interests	(14)	(19)	(14)	(22)
Net income Solvay share	**222**	**111**	**244**	**230**
Basic earnings per share from continuing operations	2.67	1.93	2.94	3.38
Basic earnings per share from discontinued operations	0.02	(0.55)	0.02	(0.55)
Basic earnings per share	2.69	1.37	2.96	2.83
Diluted earnings per share from continuing operations	2.66	1.91	2.93	3.36
Diluted earnings per share from discontinued operations	0.02	(0.55)	0.02	(0.55)
Diluted earnings per share	2.68	1.36	2.95	2.81

1. Adjusted figures exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.
2. The 2nd quarter 2011 figures were restated to show the income statement (a) as if the acquisition of Rhodia had become effective from 1st of January 2011, (b) harmonizing the accounting principles and (c) eliminating the Purchase Price Allocation (PPA) impacts.

CONSOLIDATED FINANCIAL STATEMENTS
INCOME STATEMENT 1ST SEMESTER

	IFRS		Adjusted[1]	Pro forma[2]
	2012	2011	2012	2011
Sales	**6,756**	**3,388**	**6,756**	**6,638**
Other non-core revenues	186	11	186	198
Net sales	**6,570**	**3,377**	**6,570**	**6,440**
Cost of goods sold	(5,375)	(2,675)	(5,375)	(5,129)
Gross margin	**1,381**	**713**	**1,381**	**1,509**
Commercial and administrative costs	(570)	(245)	(570)	(558)
Research and development costs	(132)	(63)	(132)	(102)
Other operating gains and losses	(93)	(12)	(24)	(22)
Earnings from associates and joint ventures accounted for using the equity method	88	22	88	33
REBITDA	**1,088**	**589**	**1,088**	**1,178**
REBIT	**675**	**416**	**744**	**860**
Non-recurring items	(39)	(1)	6	25
EBIT	**636**	**416**	**750**	**885**
Cost of borrowings	(101)	(71)	(101)	(106)
Interest on lendings and short-term deposits	10	20	10	17
Other gains and losses on net indebtedness	(5)	(5)	(5)	(13)
Cost of discounting provisions	(93)	(24)	(93)	(63)
Income/loss from available-for-sale investments	(1)	1	(1)	1
Result before taxes	**446**	**336**	**559**	**721**
Income taxes	(148)	(62)	(179)	(170)
Result from continuing operations	**298**	**274**	**380**	**551**
Result from discontinued operations	3	(44)	3	(44)
Net income	**300**	**230**	**383**	**507**
Non-controlling interests	(23)	(33)	(23)	(37)
Net income Solvay share	**278**	**197**	**360**	**470**
Basic earnings per share from continuing operations	3.35	2.98	4.36	6.33
Basic earnings per share from discontinued operations	0.03	(0.54)	0.03	(0.54)
Basic earnings per share	3.38	2.43	4.39	5.79
Diluted earnings per share from continuing operations	3.34	2.96	4.34	6.30
Diluted earnings per share from discontinued operations	0.03	(0.54)	0.03	(0.54)
Diluted earnings per share	3.37	2.42	4.37	5.76

1. Adjusted figures exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.
2. The 1st semester 2011 figures were restated to show the income statement (a) as if the acquisition of Rhodia had become effective from 1st of January 2011, (b) harmonizing the accounting principles and (c) eliminating the Purchase Price Allocation (PPA) impacts.

2012 pro forma information

The table hereafter reconciles the 2Q 2012 IFRS results (which include PPA impacts) with the 2Q 2012 Adjusted results (which exclude PPA impacts).

	IFRS 2Q 2012	PPA impacts	Adjusted 2Q 2012	IFRS 1H 2012	PPA impacts	Adjusted 1H 2012
Net Sales	3,331		3,331	6,570		6,570
REBITDA	565		565	1,088		1,088
REBIT	358	(33)	391	675	(69)	744
Non-recurring items	75		75	(39)	(45)	6
EBIT	433	(33)	466	636	(114)	750
Net financial expenses	(111)		(111)	(190)		(190)
Result before taxes	322	(33)	356	446	(114)	559
Income taxes	(88)	11	(99)	(148)	31	(179)
Net result from continuing operations	234	(22)	257	298	(82)	380
Net result from discontinued operations	1		1	3		3
Net income	236	(22)	258	300	(82)	383
Non controlling interests	(14)		(14)	(23)		(23)
Net income, Group share	222	(22)	244	278	(82)	360

Additional comments on the income statement of the 2nd quarter 2012 (IFRS/Adjusted)

Non-recurring items amounted to EUR 75 million. They primarily included EUR 115 million capital gains related to disposals of PipeLife and corporate buildings, EUR (25) million related to restructuring and reorganisation actions in the framework of the integration and Horizon deployments and EUR (9) million charges related to the revaluation of financial liabilities linked to share options held by Rhodia employees prior to the acquisition.

Financial charges amounted to EUR (111) million both on an Adjusted and an IFRS basis. The cost of borrowings amounted to EUR (50) million. Gross financial debt (EUR 3,960 million) is for 78.9% covered at a fixed average rate of 5.6% with duration of 4.5 year. Interest on cash deposits and investments amounted to EUR 4 million. The cost of discounting provisions increased to EUR (59) million vs. EUR (32) million in the prior year period. The one time effect caused by the 75 bp decrease in discount rates applicable to HSE provisions versus rates prevailing both at YE'11 and Q1'12 accounted for EUR (22) million.

Income taxes amounted to EUR (88) million in the IFRS accounts. On an Adjusted basis, income taxes totalled EUR (99) million or 28%. The EUR (11) million difference between IFRS and Adjusted figures reflects the tax impact of PPA adjustments.

Adjusted Net income amounted to EUR 258 million. On an IFRS basis, Net Income amounted to EUR 236 million, the difference is explained by the after-tax global PPA impact.

Adjusted net income, Group share amounted to EUR 244 million, resulting in EUR 2.96 Adjusted basic earnings per share.

STATEMENT OF COMPREHENSIVE INCOME (IFRS)

Million EUR	2nd quarter		1st semester	
	2012	2011	2012	2011
Net income	**236**	**131**	**300**	**230**
Gains and losses on available-for-sale financial assets	0	(3)	9	3
Gains and losses on hedging instruments in a cash flow hedge	(33)	(2)	(19)	(1)
Actuarial gains and losses on defined benefit pension plans	(184)	(12)	(247)	(23)
Currency translation differences	109	(43)	27	(196)
Share of other comprehensive income of associates and joint ventures accounted for using the equity method	(5)	(3)	15	(14)
Income tax relating to components of other comprehensive income	28	5	21	9
Other comprehensive income, net of related tax effects	**(86)**	**(58)**	**(194)**	**(224)**
Comprehensive income attributed to	**150**	**72**	**106**	**7**
Owners of the parent	136	58	82	(2)
Non-controlling interests	13	15	24	8

STATEMENT OF FINANCIAL POSITION (BALANCE SHEET)

Million EUR	June 30, 2012	December 31, 2011
Non-current assets	**12,091**	**12,064**
Intangible assets	1,633	1,705
Goodwill	2,600	2,599
Tangible assets	5,627	5,652
Available-for-sale investments	92	80
Investments in joint ventures and associates – equity method	772	704
Other investments	120	125
Deferred tax assets	838	780
Loans and other non-current assets	409	420
Current assets	**6,892**	**7,373**
Inventories	1,611	1,578
Trade receivables	2,166	2,311
Income tax receivables	57	43
Dividends receivable	6	0
Other current receivables - Financial instruments	627	464
Other current receivables – Other*	895	938
Cash and cash equivalents*	1,525	1,943
Assets held for sale	5	95
TOTAL ASSETS	**18,983**	**19,437**
Total equity	**6,667**	**6,653**
Share capital	1,271	1,271
Reserves	4,927	4,885
Non-controlling interests	470	497
Non-current liabilities	**8,576**	**8,179**
Long-term provisions: employees benefits	2,816	2,595
Other long-term provisions	1,309	1,325
Deferred tax liabilities	768	710
Long-term financial debt*	3,496	3,374
Other non-current liabilities	187	174
Current liabilities	**3,740**	**4,605**
Short-term provisions: employees benefits	43	39
Other short-term provisions	241	230
Short-term financial debt*	471	794
Trade liabilities	1,886	2,232
Income tax payable	125	51
Dividends payable	19	100
Other current liabilities	955	1,159
TOTAL EQUITY & LIABILITIES	**18,983**	**19,437**

*Net debt is the sum of Other current receivables, Cash and cash equivalents, Long-term financial debt and Short-term financial debt

STATEMENT OF CHANGES IN EQUITY

Equity attributable to equity holders of the parent

						Fair value differences					
Million EUR	Share capital	Issue premiums	Retained earnings	Treasury shares	Currency translation diff.	Available for sale investments	Cash flow hedges	Defined benefit pension plans	Total	Non-controlling interests	Total equity
Balance – 31/12/2010	**1,271**	**18**	**5,791**	**(301)**	**(374)**	**11**	**4**	**(131)**	**6,289**	**419**	**6,708**
Net profit for the period			247						247	50	296
Income and expenses directly allocated to equity					42	(8)	8	(86)	(44)	(10)	(54)
Comprehensive income	**0**	**0**	**247**	**0**	**42**	**(8)**	**8**	**(86)**	**202**	**40**	**242**
Cost of stock options			9						9		9
Dividends			(250)						(250)	(14)	(263)
Acquisition/sale of treasury shares				10					10		10
Issure of share capital									0		0
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control			(100)						(100)	52	(48)
Other			(4)						(4)	0	(4)
Balance – 31/12/2011	**1,271**	**18**	**5,693**	**(292)**	**(332)**	**3**	**12**	**(217)**	**6,156**	**497**	**6,653**
Net profit for the period			278						278	23	301
Income and expenses directly allocated to equity					34	9	(17)	(221)	(195)	1	(194)
Comprehensive income	**0**	**0**	**278**	**0**	**34**	**9**	**(17)**	**(221)**	**82**	**24**	**106**
Cost of stock options			5						5		5
Dividends			(153)						(153)	(21)	(175)
Acquisition/sale of treasury shares				106					106		106
Issure of share capital									0		0
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control			2						2	(30)	(28)
Other			0						0	0	0
Balance – 30/06/2012	**1,271**	**18**	**5,824**	**(186)**	**(299)**	**12**	**(5)**	**(438)**	**6,198**	**470**	**6,667**

CASH FLOW STATEMENT (IFRS)

Million EUR	2nd quarter		1st semester	
	2012	2011	2012	2011
EBIT	433	187	637	368
Depreciation, amortization and impairments	209	86	415	176
Changes in working capital	(101)	(48)	(321)	(294)
Changes in provisions	(58)	(42)	(59)	(48)
Dividends received from associates and joint ventures accounted for using the equity method	18	10	24	30
Income taxes paid	(45)	(45)	(65)	(57)
Others	(212)[1]	(23)	(195)	(42)
Cash flow from operating activities	**243**	**125**	**435**	**133**
Acquisition (-) of subsidiaries	0	0	0	
Acquisition (-) of investments - Other	(4)	(35)	(11)	(130)
Sale (+) of subsidiaries	0	0	0	
Sale (+) of investments - Others	170	0	173	
Acquisition (-) of tangible and intangible assets	(180)	(89)	(324)	(141)
Sale (+) of tangible and intangible assets	57	2	65	5
Income from available-for-sale investments	1	1	1	1
Changes in non-current financial assets	17	34	13	29
Cash flow from investing activities	**61**	**(88)**	**(83)**	**(236)**
Capital increase (+) / redemption (-)	(28)	(20)	(28)	(20)
Acquisition (-) / sale (+) of treasury shares	6	29	106	29
Changes in borrowings	(348)	70	(289)	50
Changes in other current financial assets	28	1,557	(151)	2,565
Cost of borrowings	(42)	(42)	(101)	(71)
Interest on lendings and short-term deposits	4	20	10	20
Other	8	(5)	(60)	(5)
Dividends paid	(171)	(168)	(261)	(267)
Cash flow from financing activities	**(544)**	**1,441**	**(775)**	**2,301**
Net change in cash and cash equivalents	**(240)**	**1,477**	**(423)**	**2,197**
Currency translation differences	12	(2)	3	(12)
Others	2	0	2	0
Opening cash balance	1,752	2,664	1,943	1,954
Closing cash balance	1,525	4,139	1,525	4,139
Free Cash Flow[2] from continuing operations	**144**	**86**	**99**	**43**
Free Cash Flow[2] from discontinued operations	**(6)**	**(14)**	**91**	**(16)**

1. Other operating cash flows include non-cash earnings from equity associates EUR (59) million, reclassification of capital gains (PipeLife and Real Estate disposals) EUR (116) million into investing cash flow, non discounting costs on HSE and pension provisions EUR (58) million and other minor non cash elements EUR 21 million
2. Cash flow from operating activities (including dividends from associates and joint ventures) + cash flow from investing activities (excluding acquisitions and sales of subsidiaries and other investments).

CASH FLOW FROM DISCONTINUED OPERATIONS

Million EUR	2nd quarter		1st semester	
	2012	2011	2012	2011
Cash flow from operating activities	(6)	(14)	91	(16)
Cash flow from investing activities	0	0	0	0
Cash flow from financing activities	0	0	(47)	0
Net change in cash and cash equivalents	**(6)**	**(14)**	**44**	**(16)**

Additional comments on the cash flow statement of the 2nd quarter 2012

Cash flow from operating activities was EUR 243 million compared to EUR 125 million last year. Besides an EBIT of EUR 433 million it consisted of

- Depreciation, amortization and impairments amounted to EUR 209
- Working capital increased by EUR 101 million

Cash flow from investing activities was EUR 61 million and capital expenditures amounted to EUR (180) million

Free Cash Flow was EUR 138 million, and included cash flow from discontinued operations for EUR (6) million linked to post-closing adjustments subsequent to the sale of the pharmaceutical activities

RESULTS BY SEGMENT BEFORE ELIMINATION OF INTER-COMPANY SALES

Million EUR	2nd quarter		1st semester	
	2012	2011	2012	2011
Net sales	**3,331**	**1,713**	**6,570**	**3,377**
Plastics				
Net sales	1,065	1,072	2,087	2,095
Inter-segments sales	(67)	(82)	(138)	(152)
External sales	998	990	1,949	1,944
Chemicals				
Net sales	789	746	1,551	1,483
Inter-segments sales	(29)	(23)	(55)	(50)
External sales	760	723	1,496	1,433
Rhodia				
Net sales	1,574		3,128	
Inter-segments sales	(1)		(3)	
External sales	1,573		3,125	
REBITDA	**565**	**304**	**1,088**	**589**
Plastics	146	200	283	366
Chemicals	139	128	294	265
Rhodia	318		579	
New Business Development	(13)	(7)	(21)	(14)
Corporate and business support	(25)	(17)	(45)	(28)
REBIT	**358**	**219**	**675**	**416**
Plastics	98	153	187	270
Chemicals	100	92	213	193
Rhodia	200		345	
New Business Development	(13)	(7)	(22)	(14)
Corporate and business support	(27)	(19)	(49)	(32)
EBIT	**433**	**233**	**636**	**416**
Plastics	164	146	248	257
Chemicals	98	116	208	210
Rhodia	180		245	
New Business Development	(13)	(7)	(22)	(14)
Corporate and business support	4	(21)	(43)	(37)

NOTES TO THE ACCOUNTS

1. Consolidated financial statements

The consolidated financial statements were prepared in conformity with IFRS standards as currently adopted in the European Union. The same accounting policies have been implemented as for the latest annual financial statements. The primary variations in scope between the first semester of 2011 and 2012 were due to:

- Treatment of the PipeLife stake in Solvay's accounts until its effective disposal in May 2012: PipeLife stake has been accounted for as an "investment held for sale" as of December 31st, 2011, following the decision to sell the 50% stake in PipeLife to Wienerberger in February 2012.

2. Content

This results report contains regulated information and is established in compliance with IAS 34. A risk analysis is included in the annual report, which is available on **www.solvay.com**.

3. Primary exchange rates

1 Euro		Closing			Average		
		6 months 2012	6 months 2011	2011	6 months 2012	6 months 2011	2011
Pound Sterling	GBP	0.807	0.903	0.835	**0.823**	0.868	0.868
American Dollar	USD	1.259	1.445	1.294	**1.296**	1.403	1.392
Argentine Peso	ARS	5.703	5.954	5.577	**5.701**	5.688	5.754
Brazilian Real	BRL	2.579	2.260	2.416	**2.414**	2.288	2.327
Thai Baht	THB	39.873	44.380	40.991	**40.372**	42.676	42.430
Japanese Yen	JPY	100.130	116.250	100.200	**103.310**	114.966	110.960

4. Purchase Price Allocation related to Rhodia's acquisition

The accounting treatment of Rhodia's acquisition is subject to Purchase Accounting (IFRS 3). More information about the accounting impacts of that acquisition on Solvay's consolidated accounts can be found in the press release on full year 2011 results.

Purchase Accounting must be completed within the 12 months following the acquisition date (September 7, 2011). Provisional accounting still prevails as:

- Some adjustments can still be reviewed and updated if applicable until September 7, 2012,
- The allocation of the goodwill that has to be done by September 7, 2012 is not completed.

5. Solvay shares

	6 months 2012	6 months 2011	2011
Number of shares issued at the end of the period	84,701,133	84,701,133	84,701,133
Average number of shares for IFRS calculation of earnings per share	81,995,834	81,150,522	81,223,941
Average number of shares for IFRS calculation of diluted income per share	82,318,495	81,586,803	81,546,384

6. Declaration by responsible persons

Jean-Pierre Clamadieu, Chief Executive Officer, and Bernard de Laguiche, Chief Financial Officer, of the Solvay Group, declare that to the best of their knowledge:

a. The summary financial information, prepared in conformity with applicable accounting standards, reflects a faithful image of the net worth, financial situation and results of the Solvay Group;

b. The intermediate report contains a faithful presentation of significant events occurring during the six first months of 2012, and their impact on the summary financial situation;

c. There are no transactions with related parties;

d. The main risks and uncertainties over the remaining months within the 2012 fiscal year stand in accordance with the assessment disclosed in the section “Risk Management” in the Solvay’s 2011 Annual Report taking into account the current economic and financial environment.

7. Limited review report

Solvay SA/NV

Limited review report on the consolidated interim financial information

for the six-month period ended 30 June 2012

To the board of directors

We have performed a limited review of the accompanying consolidated statement of financial position, the consolidated income statement, the consolidated statement of comprehensive income, the consolidated cash flow statement, the consolidated statement of changes in equity and selective notes (jointly the "interim financial information") of Solvay SA/NV ("the company") and its subsidiaries (jointly "the group") for the six-month period ended 30 June 2012. The board of directors of the company is responsible for the preparation and fair presentation of this interim financial information. Our responsibility is to express a conclusion on this interim financial information based on our review.

The interim financial information has been prepared in accordance with international financial reporting standard IAS 34 – Interim Financial Reporting as adopted by the European Union.

Our limited review of the interim financial information was conducted in accordance with international standard ISRE 2410 – Review of interim financial information performed by the independent auditor of the entity. A limited review consists of making inquiries of group management and applying analytical and other review procedures to the interim financial information and underlying financial data. A limited review is substantially less in scope than an audit performed in accordance with the International Standards on Auditing (ISA). Accordingly, we do not express an audit opinion on the interim financial information.

Based on our limited review, nothing has come to our attention that causes us to believe that the interim financial information for the six-month period ended 30 June 2012 is not prepared, in all material respects, in accordance with IAS 34 – Interim Financial Reporting as adopted by the European Union.

Diegem, 26 July 2012

The statutory auditor

DELOITTE Bedrijfsrevisoren / Reviseurs d'Entreprises

BV o.v.v.e. CVBA / SC s.f.d. SCRL

Represented by Eric Nys

GLOSSARY

Adjusted performance indicators exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.

Adjusted basic earnings per share

Basic earnings per share excluding Purchase Price Allocation (PPA) non cash accounting impacts related to the Rhodia acquisition

Adjusted net income (Solvay share)

Net income (Solvay share) excluding Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition

Adjusted net result

Net result excluding Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition

Adjusted REBIT

REBIT excluding Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition

Basic earnings per share

Net income (Solvay's share) divided by the weighted average number of shares, after deducting own shares purchased to cover stock option programs

EBIT

Earnings before interest and taxes

Free cash flow

Cash flow from operating activities + cash flow from investing activities, excluding acquisitions and sales of subsidiaries and other investments, + dividends from associates and joint ventures.

IFRS

International Financial Reporting Standards

Net sales

Sales of goods and value added services corresponding to Solvay's know-how and core business. Net sales exclude other revenues primarily comprising commodity and utility trading transactions and other revenue deemed as incidental by the Group

Pro forma figures

Figures that represent (a) as if the acquisition had become effective from 1st of January 2011, (b) harmonizing accounting principles and (c) eliminating the Purchase Price Allocation (PPA) impacts.

REBIT

Operating result, i.e. EBIT before non-recurring items

REBITDA

REBIT before depreciation and amortization

Key dates for investors

October 25, 2012: Announcement of the 3rd quarter and the nine months 2012 results and the interim dividend for 2012 (payable in January 2013, coupon no. 91) (at 07:30)

For additional information

> **Lamia Narcisse**

Media Relations
Tel: +33 (0)1 53 56 59 62

E-mail: lamia.narcisse@eu.rhodia.com

> **Maria Alcon Hidalgo**

Investor Relations
Tel: 33 (0)1 53 56 64 89

E-mail: maria.alcon-hidalgo@eu.rhodia.com

> **Erik De Leye**

Media Relations
Tel: +32 2 264 15 30

E-mail: erik.deleye@solvay.com

> **Patrick Verelst**

Investor Relations
Tel: +32 2 264 15 40

E-mail: patrick.verelst@solvay.com

Solvay Investor Relations

E-mail: investor.relations@solvay.com

SOLVAY is an international chemical Group committed to sustainable development with a clear focus on innovation and operational excellence. It generates over 90% of its sales in markets where it is among the top three leaders. Solvay offers a broad range of products that contribute to improving the quality of life and the performance of its customers in markets such as consumer goods, construction, automotive, energy, water and environment, and electronics. The Group is headquartered in Brussels, employs about 31,000 people in 55 countries and generated EUR 12.7 billion in net sales in 2011. Solvay SA (SOLB.BE) is listed on NYSE Euronext in Brussels and Paris (Bloomberg: SOLB.BB - Reuters: SOLBt.BR).

SOLVAY

a Passion for Progress®

Dit verslag is ook in het Nederlands beschikbaar – Ce rapport est aussi disponible en français